The Food and Drug Administration has expanded the indication for ribociclib in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based...
More From BioPortfolio on "FDA expands ribociclib indication in HR-positive, HER2-negative advanced or metastatic breast cancer"